ACM
PRME icon

ADAR1 Capital Management’s Prime Medicine PRME Stock Holding History

ADAR1 Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.37M Buy
1,997,552
+24,270
+1% +$80.6K 0.34% 68
2026
Q1 		$6.87M Buy
+1,973,282
New +$7.51M 0.4% 60

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

ADAR1 Capital Management's PRME Position: Q2 2026 in Review

ADAR1 Capital Management increased its Prime Medicine (PRME) stake by 1.2% in Q2 2026, buying an estimated $80.6K and bringing the position to 1,997,552 shares worth $7.37M. The position accounts for 0.34% of the portfolio, ranked #68.

ADAR1 Capital Management first reported a position in PRME in Q1 2026 and has held it in 2 quarters since. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • ADAR1 Capital Management held 1,997,552 shares of Prime Medicine worth $7.37M as of Q2 2026.
  • ADAR1 Capital Management bought 24,270 Prime Medicine shares in Q2 2026, an estimated $80.6K.
  • Prime Medicine made up 0.34% of ADAR1 Capital Management's portfolio in Q2 2026, its #68 holding.
  • ADAR1 Capital Management first reported a position in Prime Medicine in Q1 2026 and has held it in 2 quarters since.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.